Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets

Vincenza Maria Elena Bonfiglio, Andrea Russo, Matteo Fallico, Ferdinando Nicoletti, Matteo Fallico, Vincenza Bonfiglio, Michele Reibaldi, Teresio Avitabile, Emanuela Mazzon, Maria Sofia Basile, Paolo Fagone, Antonio Longo, Andrea Russo, Gabriella Mazzon

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

Uveal Melanoma (UM) represents the most common primary intraocular malignant tumor in adults. Although it originates from melanocytes as cutaneous melanoma, it shows significant clinical and biological differences with the latter, including high resistance to immune therapy. Indeed, UM can evade immune surveillance via multiple mechanisms, such as the expression of inhibitory checkpoints (e.g., PD-L1, CD47, CD200) and the production of IDO-1 and soluble FasL, among others. More in-depth understanding of these mechanisms will suggest potential targets for the design of novel and more effective management strategies for UM patients.
Original languageEnglish
Pages (from-to)1145-
Number of pages14
JournalFrontiers in Oncology
Volume9
Publication statusPublished - 2019

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets'. Together they form a unique fingerprint.

Cite this